Table 1.
Patient characteristics and clinical outcome.
| Characteristic | Abiraterone cohort (n = 86) n (%) or [IQR, 95% CI] |
Enzalutamide cohort (n = 148) n (%) or [IQR, 95% CI] |
All patients (n = 234) n (%) or [IQR, 95% CI] |
P
value |
|---|---|---|---|---|
| Agea, median, years | 78 [73-82] | 77.5 [73-82] | 78 [73-82] | .50 |
| Gleason score, median | 8 [7-9] | 8 [7-9] | 8 [7-9] | .194 |
| Surgery at diagnosis | 38 (44) | 50 (34) | 88 (38) | .149 |
| Time to CR, mo, median | 39.3 [20.5-63.4] | 30.1 [11.8-57.1] | 31.4 [14.7-58.6] | .072 |
| Sites of metastatesa | ||||
| Lymph nodes (only) | 20 (23) | 29 (20) | 49 (21) | .480 |
| Bone (non-visceral) | 56 (65) | 107 (72) | 163 (70) | |
| Visceral | 10 (12) | 12 (8) | 22 (9) | |
| PSA at Tx start, median | 11.8 [3.1-29.9] | 14.3 [5.4-35.9] | 14.0 [4.5-33.9] | .325 |
| Setting of therapy | ||||
| Pre-chemotherapy | 61 (71) | 101 (68) | 162 (69) | .222 |
| Post-chemotherapy | 17 (20) | 40 (27) | 57 (24) | |
| Post-Abi/Enza | 8 (9) | 7 (5) | 15 (6) | |
| Steroid useb (yes) | 86 (100) | 14 (9) | 100 (43) | <.001 |
| Charlson score, median | 10 [8-11] | 10 [10-12] | 10 [9-11] | .028 |
| Geriatric G8, median | 14 [12-16] | 13 [12-15] | 14 [12-15] | .081 |
| IADL, median | 6 [5-8] | 6 [5-8] | 6 [5-8] | .639 |
| Concomitant therapies, no. | 3 [1-5] | 3 [1-5] | 3 [1-5] | .671 |
| Caregiver (yes) | 71 (83) | 119 (80) | 190 (81) | .816 |
| Toxicity | ||||
| G1/G2 | 43 (50) | 91 (61) | 134 (57) | .115 |
| G3/G4 | 1 (1) | 11 (7) | 12 (5) | .074 |
Bold indicates statistically significant values.
At the time of initiation of treatment.
During the whole treatment.
Abbreviations: Abi, abiraterone; CI, confidence intervals; Δ, difference between the PSA basal value and the best response value; Enza, enzalutamide; mo., months; G, grade; IQR, interquartile range; Tx, treatment; yr, year.